english.prescrire.org > Annual Prescrire Awards > The Prescrire Awards for 2022 > The Prescrire Drug Awards for 2022 > 2022 Drug Awards > Onureg° (azacitidine): cited as Noteworthy at the 2022 Prescrire Drug Awards

The Prescrire Awards for 2022

The Prescrire Drug Awards for 2022

The Prescrire Drug Awards for 2022
Noteworthy Onureg° (azacitidine)

Le Palmarès des Médicaments Drugs deemed Noteworthy provide a modest improvement in patient care.

One drug examined in 2022 made the Noteworthy list.

• ONUREG° (azacitidine) - Bristol-Myers Squibb

Azacitidine (Onureg°) as "maintenance" therapy in acute myeloid leukaemia: substantially longer survival.

The cytotoxic drug azacitidine was evaluated as oral “maintenance” therapy in acute myeloid leukaemia in a single double-blind randomised placebo-controlled trial in 472 patients, aged 55 years or over, enrolled within 4 months of achieving remission. Median survival in the azacitidine group was longer than in the placebo group: 25 months versus 15 months.

Azacitidine can cause serious adverse effects, including haematological and gastrointestinal disorders, dyspnoea, pericarditis and necrotising fasciitis.

Azacitidine (Onureg°) was awarded a place as a Noteworthy drug because of the substantial increase in survival it offers a group of patients whose prognosis is poor. It failed to earn a place on the Honours List due to the severity of its adverse effects, which reduce patients' quality of life, and because these trial results have yet to be confirmed in another trial.

A Pilule d'Or (Golden Pill) is granted to drugs that represent a major therapeutic advance in a field in which no treatment was previously available. Drugs included on the Honours List constitute a clear advance for some patients compared with existing therapeutic options, albeit with limitations. Drugs deemed "Noteworthy" provide a modest improvement in patient care.
SEE: > About the Prescrire Drug Awards for 2022

Le Palmarès de l'information
> The Prescrire Drug Awards for 2022

Download the full article:

 FREE  "The Prescrire Awards for 2022" Prescrire International 2023; 32 (246): 80-81. (pdf, free)


Back to "The Prescrire Awards for 2022">

Produced by the Editorial Staff
©Prescrire March 2023

Share Share on Facebook Share on Twitter


Enjoy full access to Prescrire International, and support independent information